BEGIN:VCALENDAR VERSION:2.0 PRODID:-//wp-events-plugin.com//7.2.3.1//EN TZID:Europe/Helsinki X-WR-TIMEZONE:Europe/Helsinki BEGIN:VEVENT UID:48@inflames.utu.fi DTSTART;TZID=Europe/Helsinki:20210408T150000 DTEND;TZID=Europe/Helsinki:20210408T163000 DTSTAMP:20230120T083147Z URL:https://inflames.utu.fi/events/welcome-to-the-ex-vivo-models-in-immuno -oncology-research-sebinar/ SUMMARY:Welcome to the “Ex vivo models in immuno-oncology research” seb inar on 8 April 2021 at 15.00-16.30! DESCRIPTION:Cancer IO project\, coordinated by the University of Helsinki\, is starting a bi-monthly sebinar (webinar + seminar) series in April 2021 . The first session focuses on Ex vivo models in immuno-oncology research.  Welcome to join the event on in Zoom. Programme and more information be low and on Cancer IO’s website &\; LinkedIn.\n\nCancer IO Sebinar Series Session I: Ex vivo models in immuno-oncology research \n\n08.04.2 021\, 15:00-16:30 (Helsinki time)\, Zoom event \n\nThis interactive bi- monthly sebinar (seminar + webinar) series aims to bring you the newest developments in the field of immuno-oncology presented by leading scientis ts. Every sebinar will have an important interactive element in the form o f a panel discussion\, where the invited speaker discusses a timely topic with local scientists and clinicians. Sebinar attendants are welcomed to participate in the discussion using the Q&\;A feature.\n\nIn the firs t edition of the Cancer IO Sebinar series (Thursday 8.4.2021\; 15.00-16.3 0) we will hear about the latest development of patient-derived ex vivo  models in an immuno-oncology setting\, and discuss about the possible future use of these models in clinical decision making. Our invited speak ers and panelists are Dr David Barbie from Dana-Farber Cancer Institute &\; Harvard Medical School (biography below)\, Johana Kuncova-Kallio fr om UPM Biomedicals\, Peeter Karihtala from Helsinki University Hospital an d Jeroen Pouwels from University of Helsinki.\n\nProgram: \n\n15:00 - 15: 10 Introduction to ex vivo models\, Jeroen Pouwels / Research Coordinat or in Cancer IO\n\n15:10 - 15:20 3D Solutions &\; tissue preservation\ , Johana Kuncova-Kallio / Director in UPM Biomedicals\n\n15:20 - 16:10 Ex vivo systems incorporating the tumor microenvironment\, Dr. David Barb ie /  Assistant Professor in Dana-Farber Cancer Institute &\; Harvar d Medical School\n\n16:10 - 16:30 Panel discussion: The use of ex vivo cul tures in clinical decision making: Utopia or soon-to-be reality?\n\nPaneli sts: David Barbie\, Johana Kuncova-Kallio\, Jeroen Pouwels and Resea rch Director Peeter Karihtala\, Helsinki University Hospital\n\nSession Ch air: Heidi Haikala\, Cancer IO &\; Dana-Farber Cancer Institute\n\nB iography for Dr. David Barbie: \n\nDr. David A. Barbie is an Assistant Professor of Medicine at Harvard Medical School and Thoracic Oncologist a t the Dana-Farber Cancer Institute\, and an Associate Director of the Belf er Center for Science and International Affairs. He obtained an A.B. from Harvard College in 1997 and M.D. from Harvard Medical School in 2002. Dr.  Barbie was an HHMI Medical Fellow from 1999-2000 between his 2nd and 3 rd years of medical school\, working in Dr. Ed Harlow’s lab at Massachu setts General Hospital. He completed his residency in internal medicine at Massachusetts General Hospital in 2005\, followed by a year as medical ch ief resident in 2006.  Dr. Barbie was a medical oncology fellow in the Dana-Farber/Partners CancerCare program\, which he completed in 2008. Foll owing a post-doctoral fellowship in Dr. William Hahn’s lab at the Broad Institute\, he received a tenure-track independent investigator position i n 2010 at Dana-Farber\, and a clinical position within the Lowe Center for Thoracic Oncology.\n\nRecent selected publications:  \n\n\nDynamic sing le-cell RNA sequencing identifies immunotherapy persister cells following PD-1 blockade. J Clin Invest. 2021  \n\nTumor-Derived cGAMP Regulates A ctivation of the Vasculature. Front Immunol. 2020 \n\nInactivation of F bxw7 Impairs dsRNA Sensing and Confers Resistance to PD-1 Blockade. Canc er Discov. 2020  \n\nTBK1 Activation by VHL Loss in Renal Cell Carcinoma : A Novel HIF-Independent Vulnerability. Cancer Discov. 2020 \n\nUse of  Ex Vivo Patient-Derived Tumor Organotypic Spheroids to Identify Combin ation Therapies for HER2 Mutant Non-Small Cell Lung Cancer. Clin Cancer Res. 2020 \n\nEngineering approaches for studying immune-tumor cell inte ractions and immunotherapy. iScience. 2020 \n\nSuppression of STING Asso ciated with LKB1 Loss in KRAS-Driven Lung Cancer. Cancer Discov. 2019 \n \nDefining T Cell States Associated with Response to Checkpoint Immunother apy in Melanoma. Cell. 2018 \n\nA Cancer Cell Program Promotes T Cell Ex clusion and Resistance to Checkpoint Blockade. Cell. 2018 \n\nEx Vivo P rofiling of PD-1 Blockade Using Organotypic Tumor Spheroids. Cancer Disco v. 2018 Feb\;8(2):196-215. doi: 10.1158/2159-8290.CD-17-0833. Epub 2017 No v 3.PMID: 29101162  \n\nFull publication list: \n\nhttps://pubmed.ncbi .nlm.nih.gov/?term=david+barbie ATTACH;FMTTYPE=image/jpeg:https://inflames.utu.fi/wp-content/uploads/2021/ 03/io-cancer.jpg END:VEVENT BEGIN:VTIMEZONE TZID:Europe/Helsinki X-LIC-LOCATION:Europe/Helsinki BEGIN:DAYLIGHT DTSTART:20210328T040000 TZOFFSETFROM:+0200 TZOFFSETTO:+0300 TZNAME:EEST END:DAYLIGHT END:VTIMEZONE END:VCALENDAR